MONMOUTH JUNCTION, N.J., April 27, 2015 /PRNewswire/ -- CytoSorbents Corporation (NASDAQ: CTSO), a leader in critical care immunotherapy commercializing its CytoSorb® extracorporeal cytokine adsorber to purify blood and control severe inflammation, announced the appointment of Dr. Joerg Scheier, M.D. as European Medical Director.
Dr. Scheier is a specialist in intensive care medicine and anesthesiology, with more than 15 years of combined experience in treating critically-ill patients and in the design and execution of clinical trials in critical care and cardiac medical devices in Germany. Dr. Scheier joins CytoSorbents from SORIN Group, a global leader in cardiac surgery, where he served as Country Manager of Clinical Operations in Germany and led the implementation of SORIN's international clinical development and operations strategy in the country. Prior to that, he was Director of Medical Innovation and former Medical Manager of Critical Care at PULSION Medical Systems, a leader in intensive care unit (ICU) hemodynamic monitoring, acquired by Maquet Getinge Group in 2014.
Dr. Scheier brings to CytoSorbents a well-established key opinion leader network in critical care and cardiac surgery, and a wealth of experience in clinical trial design and management of both sponsor and investigator-initiated medical device clinical studies, both before and after approval. In addition, as a veteran of clinical operations and industry, he brings a diverse set of skills and expertise in regulatory affairs, medical advisory board management, product safety monitoring, sales and marketing training and support, reimbursement, project management, and the identification and evaluation of promising future technologies.
Dr. Joerg Scheier remarked, "Since starting with CytoSorbents, I have already spoken to many physicians who are seeing CytoSorb® treatment work first-hand in very difficult cases and can see their energy and enthusiasm for the therapy. My goal at CytoSorbents is to foster and grow the medical and health economics data around CytoSorb® therapy and make it a routine first-line choice by physicians to treat their patients. I truly believe that CytoSorb® has the potential to re-define critical care as a novel therapy for life-threatening conditions and holds great promise for use during and after cardiac surgery as well. The potential of CytoSorbents' portfolio of technologies fascinates me and I am excited to apply my experience, both in clinical trial management and in the care of critically-ill patients, to help bring these technologies to patients in need."
Dr. Christian Steiner, Vice President of Sales and Marketing of CytoSorbents stated, "CytoSorb® therapy has the potential to become standard of care therapy in many different clinical applications with the appropriate clinical evidence. Dr. Scheier is uniquely qualified with an extremely relevant intensive care and clinical trial background to oversee and help support more than 50 company-sponsored and investigator-initiated studies that are either being planned or are ongoing in Europe. We believe the data generated from these studies will help move CytoSorb® to a mainstream role in critical care medicine and cardiac surgery, and help drive sales and adoption throughout the world."
Dr. Scheier received his academic and medical degrees from Ludwig-Maximilians-University in Munich, Germany, and specialist training at Hospital Munich-Harlaching, a large teaching hospital in Munich, Germany. He is certified as a specialist in intensive care medicine and anaesthesia by the Bavarian Medical Association in Munich. He completed coursework for the health management at the University of Kaiserslautern in 2002.
About CytoSorbents Corporation
CytoSorbents Corporation is a critical care focused immunotherapy company using blood purification to control severe inflammation -- with the goal of preventing or treating multiple organ failure in life-threatening illnesses. Organ failure is the cause of nearly half of all deaths in the intensive care unit, with little to improve clinical outcome. CytoSorb®, the Company's flagship product, is approved in the European Union with distribution established in 29 countries around the world, as a safe and effective extracorporeal cytokine adsorber, designed to reduce the "cytokine storm" that could otherwise cause massive inflammation, organ failure and death in common critical illnesses such as sepsis, burn injury, trauma, lung injury, and pancreatitis. These are conditions where the risk of death is extremely high, yet no effective treatments exist. CytoSorb® is also being used during and after cardiac surgery to remove inflammatory mediators, such as cytokines and free hemoglobin, which can lead to post-operative complications, including multiple organ failure.
CytoSorbents' purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbents has numerous products under development based upon this unique blood purification technology, protected by 32 issued US patents and multiple applications pending, including HemoDefend™, ContrastSorb, DrugSorb, and others. Additional information is available for download on the Company's website: http://www.cytosorbents.com/.
This press release includes forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, but are not limited to, statements about our plans, objectives, representations and contentions and are not historical facts and typically are identified by use of terms such as "may," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "predict," "potential," "continue" and similar words, although some forward-looking statements are expressed differently. You should be aware that the forward-looking statements in this press release represent management's current judgment and expectations, but our actual results, events and performance could differ materially from those in the forward-looking statements. Factors which could cause or contribute to such differences include, but are not limited to, the risks discussed in our Annual Report on Form 10-K, filed with the SEC on March 31, 2015, as updated by the risks reported in our Quarterly Reports on Form 10-Q, and in the press releases and other communications to shareholders issued by us from time to time which attempt to advise interested parties of the risks and factors which may affect our business. We caution you not to place undue reliance upon any such forward-looking statements. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, other than as required under the Federal securities laws.
SOURCE CytoSorbents Corporation